Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2838330 | 0.75 | MAOB (0.39) | MAOB | |
| SCHEMBL1306041 | 0.64 | MAOB (0.57) | MAOBTAAR1 | |
| SCHEMBL2806134 | 0.63 | MAOB (0.41) | MAOB | |
| SCHEMBL28706824 | 0.62 | ATM (0.39) | MAOBCYP2D6CYP1A2CYP3A4PRMT1 | |
| SCHEMBL27651443 | 0.61 | MAOB (0.48) | MAOBCYP2D6CYP1A2CYP3A4PRMT1 | |
| SCHEMBL315315 | 0.60 | MAOB (0.52) | MAOBCYP2D6CYP1A2CYP3A4PRMT1 | |
| SCHEMBL10871836 | 0.57 | MAOB (0.43) | MAOBCYP3A4LMNA | |
| SCHEMBL6841872 | 0.57 | MAOB (0.61) | MAOBCYP2D6CYP1A2CYP3A4PRMT1 | |
| SCHEMBL28675576 | 0.57 | MAOB (0.48) | MAOBCYP2D6CYP1A2CYP3A4PRMT1 | |
| SCHEMBL28212290 | 0.57 | TAAR1 (0.52) | MAOBCYP2D6CYP1A2CYP3A4PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785574-B2 | Bridged metallocene compound, olefin polymerization catalyst containing the same, and ethylene polymer obtained with the catalyst | MITSUI CHEMICALS, INC. (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20140114031-A1 | BRIDGED METALLOCENE COMPOUND, OLEFIN POLYMERIZATION CATALYST CONTAINING THE SAME, AND ETHYLENE POLYMER OBTAINED WITH THE CATALYST | PRIME POLYMER CO., LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| EP-2218725-B1 | BRIDGED METALLOCENE OLEFIN POLYMERIZATION CATALYST AND ETHYLENE POLYMER OBTAINED BY USING THE CATALYST | MITSUI CHEMICALS INC (JP) | 2013-10-23 | — | — | EP | disclosed |
| US-20100292421-A1 | BRIDGED METALLOCENE COMPOUND, OLEFIN POLYMERIZATION CATALYST CONTAINING THE SAME, AND ETHYLENE POLYMER OBTAINED WITH THE CATALYST | MITSUI CHEMICALS, INC. | 2010-11-18 | — | — | US | disclosed |
| EP-2218725-A1 | BRIDGED METALLOCENE COMPOUND, OLEFIN POLYMERIZATION CATALYST USING THE COMPOUND AND ETHYLENE POLYMER OBTAINED BY USING THE CATALYST | Mitsui Chemicals, Inc. (JP) | 2010-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292421-A1 | BRIDGED METALLOCENE COMPOUND, OLEFIN POLYMERIZATION CATALYST CONTAINING THE SAME, AND ETHYLENE POLYMER OBTAINED WITH THE CATALYST | CAD, ENDOD1, CCT7 | MAOB 2686/4885CYP2D6 3314/4885CYP1A2 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.